caa a22 4500 469119942 CHVBK 20180323133135.0 cr unu---uuuuu 170328e19920701xx s 000 0 eng 10.1007/BF02245293 doi (NATIONALLICENCE)springer-10.1007/BF02245293 Effects of a single dose of the acetylcholinesterase inhibitor velnacrine on recognition memory and regional cerebral blood flow in Alzheimer's disease [Elektronische Daten] [K. Ebmeier, R. Hunter, S. Curran, N. Dougal, C. Murray, D. Wyper, J. Patterson, M. Hanson, K. Siegfried, G. Goodwin] The effects of a single oral dose of the acetylcholinesterase inhibitor velnacrine maleate on word and object recognition memory and regional uptake of99mTc-exametazime were examined in patients with Alzheimer's disease. Word recognition memory was marginally improved 2 h after 75 mg velnacrine. With the same dose of velnacrine a relative increase in superior frontal uptake of99mTc-exametazime was shown with single photon emission computed tomography (SPECT). This suggests increased regional perfusion and metabolism as a consequence of cholinergic stimulation. The effect did not co-vary with the degree of memory improvement, but, instead, more cognitively impaired patients showed a greater increase in tracer uptake after velnacrine, suggesting cholinergic hypersensitivity in the brains of Alzheimer patients. Springer-Verlag, 1992 Dementia nationallicence Alzheimer's disease nationallicence Acetylcholinesterase-inhibitor nationallicence Tomography, single photon emission computed nationallicence Human nationallicence Ebmeier K. MRC Brain Metabolism Unit, Royal Edinburgh Hospital, Morningside Park, EH10 5HF, Edinburgh, UK aut Hunter R. MRC Brain Metabolism Unit, Royal Edinburgh Hospital, Morningside Park, EH10 5HF, Edinburgh, UK aut Curran S. MRC Brain Metabolism Unit, Royal Edinburgh Hospital, Morningside Park, EH10 5HF, Edinburgh, UK aut Dougal N. MRC Brain Metabolism Unit, Royal Edinburgh Hospital, Morningside Park, EH10 5HF, Edinburgh, UK aut Murray C. MRC Brain Metabolism Unit, Royal Edinburgh Hospital, Morningside Park, EH10 5HF, Edinburgh, UK aut Wyper D. Institute of Neurological Sciences, Southern General Hospital, G51 4TF, Glasgow, UK aut Patterson J. Institute of Neurological Sciences, Southern General Hospital, G51 4TF, Glasgow, UK aut Hanson M. Institute of Neurological Sciences, Southern General Hospital, G51 4TF, Glasgow, UK aut Siegfried K. Hoechst AG, W-6230, Frankfurt am Main 80, Federal Republic of Germany aut Goodwin G. MRC Brain Metabolism Unit, Royal Edinburgh Hospital, Morningside Park, EH10 5HF, Edinburgh, UK aut Psychopharmacology Springer-Verlag 108/1-2(1992-07-01), 103-109 0033-3158 108:1-2<103 1992 108 213 https://doi.org/10.1007/BF02245293 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF02245293 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Ebmeier K. MRC Brain Metabolism Unit, Royal Edinburgh Hospital, Morningside Park, EH10 5HF, Edinburgh, UK aut NATIONALLICENCE 700 1- Hunter R. MRC Brain Metabolism Unit, Royal Edinburgh Hospital, Morningside Park, EH10 5HF, Edinburgh, UK aut NATIONALLICENCE 700 1- Curran S. MRC Brain Metabolism Unit, Royal Edinburgh Hospital, Morningside Park, EH10 5HF, Edinburgh, UK aut NATIONALLICENCE 700 1- Dougal N. MRC Brain Metabolism Unit, Royal Edinburgh Hospital, Morningside Park, EH10 5HF, Edinburgh, UK aut NATIONALLICENCE 700 1- Murray C. MRC Brain Metabolism Unit, Royal Edinburgh Hospital, Morningside Park, EH10 5HF, Edinburgh, UK aut NATIONALLICENCE 700 1- Wyper D. Institute of Neurological Sciences, Southern General Hospital, G51 4TF, Glasgow, UK aut NATIONALLICENCE 700 1- Patterson J. Institute of Neurological Sciences, Southern General Hospital, G51 4TF, Glasgow, UK aut NATIONALLICENCE 700 1- Hanson M. Institute of Neurological Sciences, Southern General Hospital, G51 4TF, Glasgow, UK aut NATIONALLICENCE 700 1- Siegfried K. Hoechst AG, W-6230, Frankfurt am Main 80, Federal Republic of Germany aut NATIONALLICENCE 700 1- Goodwin G. MRC Brain Metabolism Unit, Royal Edinburgh Hospital, Morningside Park, EH10 5HF, Edinburgh, UK aut NATIONALLICENCE 773 0- Psychopharmacology Springer-Verlag 108/1-2(1992-07-01), 103-109 0033-3158 108:1-2<103 1992 108 213 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer